All News

    Bexobrutideg Receives Orphan Drug Designation in Waldenström Macroglobulinemia

    March 17th 2025, 7:00pm

    Article

    Bexobrutideg, a bioavailable agent, was granted orphan drug designation by the FDA for Waldenström macroglobulinemia, a type of non-Hodgkin's lymphoma.

    Registration Open for the 2025 Know All Your Treatment Options Webinar Hosted by the End Brain Cancer Initiative

    March 17th 2025, 5:27pm

    Article

    A Picture is Worth Ten Thousand Words When it Comes to Cancer

    March 17th 2025, 5:00pm

    Article

    Years after losing my brother to Hodgkin’s lymphoma, I learned something about how he felt facing a terminal diagnosis by studying an old Polaroid.

    Precision Radiation Therapy Makes Strides in Colorectal Cancer Care

    March 17th 2025, 4:00pm

    Video

    Dr. Yufei Liu discusses how updates to precision radiation therapy are reshaping colorectal cancer care.

    FDA Grants Orphan Drug Designation to PEP-010 in Pancreatic Cancer

    March 17th 2025, 3:00pm

    Article

    The FDA has granted orphan drug designation to PEP-010 for pancreatic cancer, advancing its development as a potential novel treatment for the disease.

    SBRT May Offer Best Control Rates for Larger RCC Tumors, Study Finds

    March 17th 2025, 1:00pm

    Article

    Among patients with renal cell carcinoma, those with larger tumors may yield the most benefit from SBRT compared with other ablative options.

    Jakafi May Not Associate with Long-Term Benefits in Myelofibrosis Subset

    March 16th 2025, 6:00pm

    Article

    Real-world data suggest Jakafi shows limited benefits in CALR-mutated myelofibrosis.

    Why It’s Important to Have Hard Conversations in Breast Cancer Care

    March 16th 2025, 2:00pm

    Article

    CURE spoke with Kelly Grosklags of Conversations With Kelly at the Miami Breast Cancer Conference.

    Ongoing Trials Aim to Advance HER2-Negative Breast Cancer Treatment

    March 15th 2025, 6:00pm

    Article

    Dr. Kevin Kalinsky covers the gamut of the current treatment landscape for patients with HER2-negative breast cancer, highlighting recent advancements.

    Jelmyto Maintains Effectiveness Over Time in Bladder Cancer Subtype

    March 15th 2025, 2:00pm

    Article

    Jelmyto demonstrated long-term efficacy in low-grade upper tract urothelial carcinoma, with most maintaining complete response after several months.